The Epigenetics Market is projected to reach US$ 2,611.57 million by 2025 from US$ 991.45 million in 2017; it is expected to grow at a CAGR of 13.6% from 2017 to 2025.
The declining costs associated with different strategies and methods for sequencing supports to influence the scale and scope of almost all genomic research projects. The costs associated with DNA sequencing performed at the sequencing centers which is funded by the Institutes, has tracked by the National Human Genome Research Institute (NHGRI) for many years. This information has served as a key standard for establishing the DNA sequencing capacity and considering improvements in DNA sequencing technologies of the NHGRI Genome Sequencing Program (GSP). In the recent years, next generation sequencing price have declined substantially. For instance, first whole human genome sequencing cost over US$3.7 billion in 2000 and took 13 years for the completion. However, the costs for the same in recent years has reduced to US$1,000 and the process requires less number of days. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Major market players such as Illumina and Roche have introduced breakthrough technologies that have enabled in the cost and time reduction in the sequencing. Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing, that upsurge the growth of the market.
Get Sample PDF:
The epigenetics market is driven by the driving factor such as declining prices of sequencing, and is likely to drive the market in the coming years. The declining costs associated with different strategies and methods for sequencing supports to influence the scale and scope of almost all genomic research projects. In 2000, cost for sequencing was US$ 3.7 billion, which dropped down to US$ 10 million in 2006 and declined to US$ 5,000 in 2012. Owing to factors such as advances in the field of genomics, development in different methods and strategies for sequencing, there is a notable decline in the cost of sequencing, that upsurge the growth of the market.The market is likely to restrain its growth due to the factors such as high cost of advanced technologies. Companies such as Illumina and PacBio offer instruments with high cost. For instance, Illumina MiSeq cost for US$ 128,000 and PacBio RS cost for US$ 695,000. Thus, the high cost of next generation sequencers is hindering the growth of the market for in the future. Whereas the use of the neuroepigenetics to diagnose the neurodevelopmental disorders is likely to contribute a potential market growth in the forecast period.
Some of the major primary and secondary sources included in the report epigenetics market are National Institute of Environmental Health Sciences (NIEHS), Epidemiology and Genomics Research Program (EGRP), Canadian Institutes of Health Research (CIHR), Synthetic Biology Leadership Council, Chinese Academy of Sciences, World Health Organization, European Union, Food and Drug Administration and more.
In recent years, the psychologists are focusing to pioneer the fields of epigenetics and neurogenetics to introduce better therapies and treatment for brain related disorders. The psychologists are putting their efforts that vastly improving the treatments for mental illness and neurodevelopmental disorders such as autism and attention-deficit/hyperactivity disorder (ADHD). For the research and development in this field, many individual institutes such as, the National Institute on Drug Abuse (NIDA), the National Institute on Alcohol Abuse and Alcoholism and the National Institute of Mental Health providing generous funding in the epigenetics area. Moreover, in the year 2014 and 2016, the NIDA grants $12 million to each two groups for the research about the link between behavior related to drug abuse and genes. The neurogenetics addresses gene-related phenomena which is related to the brain and central nervous system. Where the epigenetics comprises the opportunity to examine and control the behavioral influences on genetic programming. The epigenetics provide new tools for enabling this work to proceed with unprecedented accuracy. With the new technology, researchers collect specific DNA samples from various sources such as, blood or saliva and brain tissue to observe the DNA sequence and map out in fine detail about the methylation patterns within a particular gene segment or even a single gene.
The report segments the global epigenetics market as follows:
· Bioinformatics Tools Global epigenetics Market – By Technology
- Histone Modification
- DNA Methylation
· Global epigenetics Market – By Application
- Metabolic Diseases
- Cardiovascular Diseases
The List of Companies
- Merck KGaA
2. Thermo Fisher Scientific, Inc.
3. Abcam plc
4. Agilent Technologies
5. Active Motif
7. Bio-Rad Laboratories, Inc.
8. PerkinElmer Inc.
9. New England Biolabs (NEB)
10. Illumina, Inc.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi